Johannes Berges
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johannes Berges has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Cindy Flamann
Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany
3 shared publicationsHeiko Bruns
Department of Pediatrics and Adolescent Medicine, FAU Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen 91054, Germany
3 shared publicationsAdrian Weich
Hautklinik, Universitätsklinikum Erlangen, Erlangen, Germany
1 shared publication- Alessandra Moretti
First Department of Medicine, Cardiology, Klinikum Rechts der Isar Technical University of Munich Munich Germany
1 shared publication - Alexander Schnell
Department of Pediatrics and Adolescent Medicine, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Loschgestr. 15, 91054 Erlangen, Germany
1 shared publication Alma Zernecke
Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany
1 shared publication
Latest Publications
- 11 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (11) , 1359-1373
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT
Graft-versus-host disease (GVHD) ensues as the most common nonrelapse complication after allogeneic hematopoietic cell transplantation (allo-HCT). A pivotal goal in GVHD management revolves around quelling inflammation. Phagocytic clearance of inflammatory cells contributes substantially to termination of inflammatory processes. Nevertheless, the precise functions of phagocytosis in GVHD remain largely unclear. In this study, we identified the “do not eat me” signal CD47 as a promising target for therapeutic interventions aimed at eradicating alloreactive T cells subsequent to allo-HCT. Analysis of global data sets revealed a remarkable upregulation of CD47 expression on T cells residing in the ileum of patients with inflamed intestine. Building on this finding, we examined CD47 levels in the gastrointestinal tract (GIT) after allo-HCT. Our work not only confirmed upregulated CD47 expression in the GIT of GVHD patients but also identified CD47 on T cells in the ileum of GVHD mice after allo-HCT. Additionally, we found that activated donor T cells suppress antibody-dependent cellular phagocytosis (ADCP) via CD47 signaling in vitro. Application of anti-CD47 antibodies significantly invigorated the impaired ADCP of activated T cells. Administering anti-CD47 antibodies to mice elevated phagocytosis of T cells in the GIT, induced immunosuppressive responses, and improved survival. Finally, transplantation of CD47-deficient donor T cells significantly improved clinical GVHD score with improved survival after allo-HCT. Collectively, our findings illuminate CD47 upregulation as a pivotal mechanism in patients with GVHD, leading to impaired phagocytic clearance of alloreactive T cells. This study proposes that anti-CD47 treatment could rectify the compromised phagocytosis of alloreactive T cells, thereby aiding in the resolution of inflammation after allo-HCT.
- 11 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (11) , 1359-1373
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT
Graft-versus-host disease (GVHD) ensues as the most common nonrelapse complication after allogeneic hematopoietic cell transplantation (allo-HCT). A pivotal goal in GVHD management revolves around quelling inflammation. Phagocytic clearance of inflammatory cells contributes substantially to termination of inflammatory processes. Nevertheless, the precise functions of phagocytosis in GVHD remain largely unclear. In this study, we identified the “do not eat me” signal CD47 as a promising target for therapeutic interventions aimed at eradicating alloreactive T cells subsequent to allo-HCT. Analysis of global data sets revealed a remarkable upregulation of CD47 expression on T cells residing in the ileum of patients with inflamed intestine. Building on this finding, we examined CD47 levels in the gastrointestinal tract (GIT) after allo-HCT. Our work not only confirmed upregulated CD47 expression in the GIT of GVHD patients but also identified CD47 on T cells in the ileum of GVHD mice after allo-HCT. Additionally, we found that activated donor T cells suppress antibody-dependent cellular phagocytosis (ADCP) via CD47 signaling in vitro. Application of anti-CD47 antibodies significantly invigorated the impaired ADCP of activated T cells. Administering anti-CD47 antibodies to mice elevated phagocytosis of T cells in the GIT, induced immunosuppressive responses, and improved survival. Finally, transplantation of CD47-deficient donor T cells significantly improved clinical GVHD score with improved survival after allo-HCT. Collectively, our findings illuminate CD47 upregulation as a pivotal mechanism in patients with GVHD, leading to impaired phagocytic clearance of alloreactive T cells. This study proposes that anti-CD47 treatment could rectify the compromised phagocytosis of alloreactive T cells, thereby aiding in the resolution of inflammation after allo-HCT.
- 22 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (782) , eadk9145
Perinatal dysfunction of innate immunity in cystic fibrosis
In patients with cystic fibrosis (CF), repeated cycles of infection and inflammation eventually lead to fatal lung damage. Although diminished mucus clearance can be restored by highly effective CFTR modulator therapy, inflammation and infection often persist. To elucidate the role of the innate immune system in CF etiology, we investigated a CF pig model and compared these results with those for preschool children with CF. In newborn CF pigs, we observed changes in lung immune cell composition before the onset of infection that were dominated by increased monocyte infiltration, whereas neutrophil numbers remained constant. Flow cytometric and transcriptomic profiling revealed that the infiltrating myeloid cells displayed a more immature status. Cells with comparably immature transcriptomic profiles were enriched in the blood of CF pigs at birth as well as in preschool children with CF. This pattern coincided with decreased CD16 expression in the myeloid cells of both pigs and humans, which translated into lower phagocytic activity and reduced production of reactive oxygen species in both species. These results were indicative of a congenital, translationally conserved, and functionally relevant aberration of the immune system in CF. In newborn wild-type pigs, CFTR transcription in immune cells, including lung-derived and circulating monocytes, isolated from the bone marrow, thymus, spleen, and blood was below the detection limits of highly sensitive assays, suggesting an indirect etiology of the observed effects. Our findings highlight the need for additional immunological treatments to target innate immune deficits in patients with CF.
- 22 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (782) , eadk9145
Perinatal dysfunction of innate immunity in cystic fibrosis
In patients with cystic fibrosis (CF), repeated cycles of infection and inflammation eventually lead to fatal lung damage. Although diminished mucus clearance can be restored by highly effective CFTR modulator therapy, inflammation and infection often persist. To elucidate the role of the innate immune system in CF etiology, we investigated a CF pig model and compared these results with those for preschool children with CF. In newborn CF pigs, we observed changes in lung immune cell composition before the onset of infection that were dominated by increased monocyte infiltration, whereas neutrophil numbers remained constant. Flow cytometric and transcriptomic profiling revealed that the infiltrating myeloid cells displayed a more immature status. Cells with comparably immature transcriptomic profiles were enriched in the blood of CF pigs at birth as well as in preschool children with CF. This pattern coincided with decreased CD16 expression in the myeloid cells of both pigs and humans, which translated into lower phagocytic activity and reduced production of reactive oxygen species in both species. These results were indicative of a congenital, translationally conserved, and functionally relevant aberration of the immune system in CF. In newborn wild-type pigs, CFTR transcription in immune cells, including lung-derived and circulating monocytes, isolated from the bone marrow, thymus, spleen, and blood was below the detection limits of highly sensitive assays, suggesting an indirect etiology of the observed effects. Our findings highlight the need for additional immunological treatments to target innate immune deficits in patients with CF.
- Open Access
- 18 June 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 17 (5) , 892-910
Cell type-specific modulation of metabolic, immune-regulatory, and anti-microbial pathways by CD101
- 18 June 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 17 (5) , 892-910
Open AccessCell type-specific modulation of metabolic, immune-regulatory, and anti-microbial pathways by CD101
- Open Access
- 9 May 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (5) , e008104
Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy
Background Tumor-associated antigens and their derived peptides constitute an opportunity to design off-the-shelf mainline or adjuvant anti-cancer immunotherapies for a broad array of patients. A performant and rational antigen selection pipeline would lay the foundation for immunotherapy trials with the potential to enhance treatment, tremendously benefiting patients suffering from rare, understudied cancers. Methods We present an experimentally validated, data-driven computational pipeline that selects and ranks antigens in a multipronged approach. In addition to minimizing the risk of immune-related adverse events by selecting antigens based on their expression profile in tumor biopsies and healthy tissues, we incorporated a network analysis-derived antigen indispensability index based on computational modeling results, and candidate immunogenicity predictions from a machine learning ensemble model relying on peptide physicochemical characteristics. Results In a model study of uveal melanoma, Human Leukocyte Antigen (HLA) docking simulations and experimental quantification of the peptide–major histocompatibility complex binding affinities confirmed that our approach discriminates between high-binding and low-binding affinity peptides with a performance similar to that of established methodologies. Blinded validation experiments with autologous T-cells yielded peptide stimulation-induced interferon-γ secretion and cytotoxic activity despite high interdonor variability. Dissecting the score contribution of the tested antigens revealed that peptides with the potential to induce cytotoxicity but unsuitable due to potential tissue damage or instability of expression were properly discarded by the computational pipeline. Conclusions In this study, we demonstrate the feasibility of the de novo computational selection of antigens with the capacity to induce an anti-tumor immune response and a predicted low risk of tissue damage. On translation to the clinic, our pipeline supports fast turn-around validation, for example, for adoptive T-cell transfer preparations, in both generalized and personalized antigen-directed immunotherapy settings.
- 9 May 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (5) , e008104
Open AccessGene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy
Background Tumor-associated antigens and their derived peptides constitute an opportunity to design off-the-shelf mainline or adjuvant anti-cancer immunotherapies for a broad array of patients. A performant and rational antigen selection pipeline would lay the foundation for immunotherapy trials with the potential to enhance treatment, tremendously benefiting patients suffering from rare, understudied cancers. Methods We present an experimentally validated, data-driven computational pipeline that selects and ranks antigens in a multipronged approach. In addition to minimizing the risk of immune-related adverse events by selecting antigens based on their expression profile in tumor biopsies and healthy tissues, we incorporated a network analysis-derived antigen indispensability index based on computational modeling results, and candidate immunogenicity predictions from a machine learning ensemble model relying on peptide physicochemical characteristics. Results In a model study of uveal melanoma, Human Leukocyte Antigen (HLA) docking simulations and experimental quantification of the peptide–major histocompatibility complex binding affinities confirmed that our approach discriminates between high-binding and low-binding affinity peptides with a performance similar to that of established methodologies. Blinded validation experiments with autologous T-cells yielded peptide stimulation-induced interferon-γ secretion and cytotoxic activity despite high interdonor variability. Dissecting the score contribution of the tested antigens revealed that peptides with the potential to induce cytotoxicity but unsuitable due to potential tissue damage or instability of expression were properly discarded by the computational pipeline. Conclusions In this study, we demonstrate the feasibility of the de novo computational selection of antigens with the capacity to induce an anti-tumor immune response and a predicted low risk of tissue damage. On translation to the clinic, our pipeline supports fast turn-around validation, for example, for adoptive T-cell transfer preparations, in both generalized and personalized antigen-directed immunotherapy settings.
- Open Access
- 1 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (8) , 2149-2158.e10
Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System
- 1 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (8) , 2149-2158.e10
Open AccessTranscriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System